Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report

Journal of Medical Microbiology and Infectious Diseases Pub Date : 2021-12-01 DOI:10.52547/jommid.9.4.225

T. Rostami, N. Alijani, A. Kiumarsi, S. Rad, S. Mirhoseini, Mohammadreza Rostami, A. Hesabi, S. Mousavi, S. Mousavi

引用次数: 0

Abstract

Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report Tahereh Rostami , Neda Alijani , Azadeh Kiumarsi , Soroush Rad , Seied Amirhosein Mirhoseini , Mohammadreza Rostami , Amir Hesabi , Seyed Ali Mousavi , Seied Asadollah Mousavi Department of Pediatric Cell Therapy, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran; Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

查看原文本刊更多论文

托珠单抗治疗造血干细胞移植后COVID-19:一份儿科病例报告

Tahereh Rostami, Neda Alijani, Azadeh Kiumarsi, Soroush Rad, Seied Amirhosein Mirhoseini, Mohammadreza Rostami, Amir Hesabi, Seyed Ali Mousavi, Seied Asadollah Mousavi儿科细胞治疗系，肿瘤学，血液学和细胞治疗研究所，伊朗德黑兰;德黑兰医科大学肿瘤学、血液学和细胞治疗研究所传染病系，伊朗德黑兰;德黑兰医科大学肿瘤学、血液学和细胞治疗研究所，伊朗德黑兰

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Microbiology and Infectious Diseases

自引率

0.00%

发文量

审稿时长

12 weeks